EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rational Design and Evaluation of Novel TGR5 Agonists for Diabetes

Rachana S Bhimanwar iD, Zachary Detwiler iD, Jinge G Zhu, Samuel T Saghafi iD, Carolyn A Winder, Dawn Belt Davis iD, Amit Mittal, Vikas Sharma iD, David A Harris iD, Snehal N Chaudhari iD

Molecules · 26.03.2026 · 31 (7) · 1093

DOI: 10.3390/molecules31071093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 26.03.2026. Verfasst von Rachana S Bhimanwar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pune 411018, India. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Drug Design, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, University of Wisconsin-Madison.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Agonists of the G protein-coupled receptor TGR5 have long been sought-after for their metabolic benefits. Intestinal TGR5 activation induces secretion of the antidiabetic hormone GLP-1, which can systemically improve diabetes phenotypes in multiple organs. However, no TGR5 agonist drug candidate has succeeded in clinical trials due to their low potency and unwanted side effects. A challenge in the field has been the development of TGR5 agonists that are non-toxic, long-acting, and have functional selectivity for G protein-biased agonism. In this study, we propose a systematic pipeline for engineering optimal TGR5 agonists with antidiabetic properties. This pipeline is interdisciplinary, combining in silico, in vitro, and in vivo assays to design and validate drug candidates. We identify 2 lead compounds that outline the necessary beneficial properties for a successful TGR5 agonist against diabetes. We uncover the molecular mechanisms that allow TGR5 agonists to induce the transcription of their target, TGR5, in intestinal enteroendocrine cells. Lastly, we investigate the molecular interactions of our lead candidates in the TGR5 binding pocket to identify optimal parameters for stability and biological activity. Our strategy for TGR5 agonist design and evaluation has the potential to guide the discovery process for targeted TGR5 therapeutics for metabolic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, G-Protein-CoupledDrug DesignHypoglycemic AgentsAnimalsHumansMiceMolecular Docking SimulationEnteroendocrine CellsGlucagon-Like Peptide 1

Stichwörter der Autor:innen

G protein biasGLP-1T2DTGR5diabetessmall molecules

Substanzen

Receptors, G-Protein-CoupledGPBAR1 protein, humanHypoglycemic AgentsGlucagon-Like Peptide 1

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pune 411018, India.
  • Department of Pharmaceutical Chemistry, School of Pharmacy and Research, Dnyaan Prasad Global University, Pune 411018, India.
  • Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, India.
  • Wisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI 53706, USA.
  • Wisconsin Surgical Laboratory in Metabolism (WiSLiM), Department of Surgery, University of Wisconsin-Madison, Madison, WI 53705, USA.
  • Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.

ORCID-Profile: Rachana S Bhimanwar, Zachary Detwiler, Samuel T Saghafi, Dawn Belt Davis, Vikas Sharma, David A Harris, Snehal N Chaudhari

Förderung

  • NIDDK NIH HHS
  • University of Wisconsin-Madison

Zitieren

APA

Bhimanwar, R. S., Detwiler, Z., Zhu, J. G., Saghafi, S. T., Winder, C. A., Davis, D. B., Mittal, A., Sharma, V., Harris, D. A., & Chaudhari, S. N. (2026). Rational Design and Evaluation of Novel TGR5 Agonists for Diabetes. Molecules, 31(7), 1093. https://doi.org/10.3390/molecules31071093

Vancouver

Bhimanwar RS, Detwiler Z, Zhu JG, Saghafi ST, Winder CA, Davis DB, et al. Rational Design and Evaluation of Novel TGR5 Agonists for Diabetes. Molecules. 2026;31(7):1093. doi:10.3390/molecules31071093

BibTeX
@article{Bhimanwar2026,
  author = {Bhimanwar, Rachana S and Detwiler, Zachary and Zhu, Jinge G and Saghafi, Samuel T and Winder, Carolyn A and Davis, Dawn Belt and Mittal, Amit and Sharma, Vikas and Harris, David A and Chaudhari, Snehal N},
  title = {Rational Design and Evaluation of Novel TGR5 Agonists for Diabetes},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {7},
  pages = {1093},
  doi = {10.3390/molecules31071093}
}
Kostenlos starten →